Antiseizure Drugs and Pharmacogenetics—Is There Signal in the Noise?
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.25600 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Network Open, 2024. Verfasst von David J Gagnon. Beteiligte Einrichtung: Department of Pharmacy, Maine Medical Center, Portland. Hauptthemen laut MEDLINE: Anticonvulsants, Pharmacogenetics. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Potassium bromide was the first antiseizure drug in 1857 and was the only agent used clinically until 1912 when phenobarbital was discovered. 1 Since 1975, there have been 28,000 new chemical entities studied as antiseizure drugs with approximately 30 (0.1%) of them ultimately being approved by the Food and Drug Administration. 1 Antiseizure drugs often have narrow therapeutic windows and therapeutic drug monitoring is recommended during therapy.The International League against Epilepsy began issuing guidance on therapeutic drug monitoring in 1993 and released their most recent iteration in 2008. 2 Interestingly, the 2008 iteration included a single reference on pharmacogenetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Maine Medical Center, Portland.
- Tufts University School of Medicine, Boston, Massachusetts.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Gagnon, D. J. (2024). Antiseizure Drugs and Pharmacogenetics—Is There Signal in the Noise?. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.25600
Vancouver
Gagnon DJ. Antiseizure Drugs and Pharmacogenetics—Is There Signal in the Noise?. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.25600
BibTeX
@article{Gagnon2024,
author = {Gagnon, David J},
title = {Antiseizure Drugs and Pharmacogenetics—Is There Signal in the Noise?},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.25600}
}
EUVIMED